SPONDYLOARTHRITIS (SpA) PATIENTS (PsA, AS, and nr-axSpA) Your choice of a biologic in patients with SpA is mostly influenced by: Choices Disease activity Patient preference Dosing Insurance/coverage MD experience What percentage of your SpA patients are adherent to prescribed therapy? Choices Less than 25% 26% to 50% More than 50% I don’t know Who is the ideal patient to receive an intravenous biologic formulation? Choices Obese (BMI >30) Older age (>65 years) Multiple comorbidities Patient adherence Patient preference All the above Why would you use an IV formulation of secukinumab? Choices I have access to an infusion center Patients with SC injection-site reactions Medicare patients I won’t use IV secukinumab How many SpA patients do you currently treat? Choices <100 100-200 201-300 301-400 401-500 >500 SpA patients not responding to first-line therapy, which treatment do you prefer? Choices TNF inhibitors IL-17 inhibitors IL-23 inhibitors JAK inhibitors csDMARDs When it comes to recommending treatment for patients, I tend to be: Choices Realistic (prioritize patient factors) Optimistic (prioritize efficacy) Conservative (prioritize safety) I am... Choices A Rheumatologist A Fellow/Trainee An NP/PA Pharma Other
